Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2002

View Archived Issues

Research snapshots in sexual dysfunction

Schering-Plough reports Clarinex launch imminent

Third Wave and Daiichi to develop diagnostic products for use with irinotecan

FDA approves Uni-Gold Strep A rapid test

Sweden expands approved use of Viragen's natural interferon alfa

MorphiDex patient enrollment progressing behind schedule

Mechanism and potential treatments for learning disability in NF1 patients identified

Pharmacia's broad R&D pipeline includes two potential blockbusters

Mechanism of analgesic effect of Esterom identified by Brigham & Women's team

Large, long-term study in Australia seeking optimal HIV treatment strategy

Beneficial effects reported for antisense inhibition of MIP-1alpha in multiple myeloma

Vivus cleared to proceed with TA-1790 trial in erectile dysfunction

Patient treatment commences in phase II trial of RSD-1235 in atrial fibrillation

Arius postpones murine ARH460-23 antibody development

DMXAA in combination with chemotherapy produces positive results in mice

Preparations under way for trial of Ampakine in mild cognitive impairment

Therapeutic potential of IL-18 neutralization examined in mouse model of arthritis

P&G assumes marketing of Asacol in the U.K.

Phenyl-substituted heterocyclic ketones with selective COX-2-inhibitory activity

Aventis synthesizes urea and thiourea derivatives as inhibitors of factor VIIa

Melanocortin receptor agonists and uses thereof claimed by Merck

New GSK compounds useful for treatment and prophylaxis of sCD23-mediated conditions

Takeda presents new inhibitors of tyrosine phosphatases

Ligands for the benzodiazepine site on GABA-A receptors in the Neurogen pipeline

New metabolically stable gabapentin analogues described in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...